Trial reportEuropean journal of pediatrics2026
Impact of a multiplex respiratory PCR panel on antibiotic stewardship in hospitalized pediatric pneumonia: a randomized clinical trial.
Trial report in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate whether the FILMARRAY® Pneumonia Panel (FAPP) added to standard care could effectively guide antibiotic prescriptions in hospitalized pediatric patients with infectious pneumonia. In this single-center, open-label, parallel-group randomized controlled clinical trial, we enrolled hospitalized children (28 days to 18 years old) diagnosed with infectious pneumonia. Participants were randomized to standard care only (control) or to added FAPP (intervention group). The primary outcome was the proportion of patients with antibiotic change within 72 h. Between December 8, 2021, and February 16, 2023, we enrolled 315 patients (157 in the intervention group and 158 in the control group). Pathogens were detected in 86.6% (32.7% bacterial, 56.5% viral, and 10.9% atypical) via FAPP, which may encompass colonizing organisms due to its enhanced sensitivity. The primary outcome was comparable between the intervention and control groups (51.6%, 81/157, versus 49.4%, 78/158; P = 0.693). However, key exploratory secondary outcomes demonstrated significant improvements in the intervention group: total frequency of changes in antibiotic and antiviral agents based on pathogen results (47.8%, 75/157, versus 25.3%, 40/158; P < 0.001) and proportion of patients with antibiotic de-escalation within 72 h (14.6%, 23/157, versus 1.9%, 3/158; P < 0.001).
conclusionIntegrating FILMARRAY® into pediatric pneumonia clinical management did not significantly boost initial overall antibiotic modification rates. However, exploratory analysis showed it improved targeted antimicrobial adjustments and facilitated antibiotic de-escalation, suggesting FILMARRAY® may add value to antibiotic stewardship. Subsequent trials could substantiate this theoretical proposition.
trial registrationChictr.org.cn, ChiCTR2100047213, registered 11 June 2021-prospectively registered, https://www.chictr.org.cn/showproj.html?proj=128024 . WHAT IS KNOWN: • FILMARRAY® molecular techniques, via semiquantitative analysis to identify potential pathogens, may contribute to reduce antibiotic usage and facilitate more targeted and appropriate antibiotic therapy in adult patients with lower respiratory tract infections. WHAT IS NEW: • Integrating FILMARRAY® into pediatric pneumonia care did not notably raise initial overall antibiotic modification rates. However, exploratory analysis showed it improved targeted antimicrobial adjustments and promoted antibiotic de-escalation, suggesting potential value for antibiotic stewardship.
Indexed as
Identifiers
42287352What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.